A new portal connecting the IMPI and Cofepris aims to increase transparency and efficiency in Mexico's pharmaceutical system, addressing a long-standing issue with conflicting patent regulations. The portal has the potential to simplify the approval process for generic medications, but its implementation has been marred by controversy and disputes over patent interpretation.